The role of WT1 gene in neuroblastoma

Quantitative Assessment of Wilms Tumor 1 (WT1) Gene Transcripts in Egyptian Acute Lymphoblastic Leukemia Patients

“…The oncogenic properties of the WT1 gene have recently been reported in various malignancies. 29 Peptides from WT1, upregulated in many hematopoietic and solid tumors, can be recognized by T cells, and numerous efforts are underway to engineer WT1-based cancer vaccines. 30 Clinical trials of WT1 peptide-based immunotherapy for cancer have already been started, and WT1 peptide vaccination has been shown to be safe and clearly effective against several types of adulthood leukemia and solid cancers.…”

Immunohistochemistry as potential diagnostic pitfall in the most common solid tumors of children and adolescents

“…Neuroblastoma, the most undifferentiated form, is traditionally considered as a WT1-negative tumor. However a few studies have shown a variable (often focal and weak) nuclear and/or cytoplasmic expression of WT1 in this tumor (Barnoud et al, 2000;Carpentieri et al, 2002;Sebire et al, 2005;Wang et al, 2011). Therefore some diagnostic problems may arise with other SRBCTs which express WT1 at both nuclear and cytoplasmic level, such as DSRCT, rhabdomyosarcoma, and EWS/pPNET.…”

Oncofetal expression of Wilms’ tumor 1 (WT1) protein in human fetal, adult and neoplastic skeletal muscle tissues

“…In the last two decades WT1 nuclear expression has also been detected in other tumors, such as mesothelial and ovarian tumors, Sertoli cell tumor, desmoplastic small round cell tumor (Kumar-Singh et al, 1997;Shimizu et al, 2000;Zhang et al, 2003;Nakatsuka et al, 2006;Zhao et al, 2007). Since new recently generated antibodies against the N-terminal portion (clone 6F-H2) of WT1 are commercially available, an increasing number of benign and malignant tumors which exhibit exclusively WT1 cytoplasmic expression has been documented (Ueda et al, 2003;Lawley et al, 2005;Timár et al, 2005;Al Dhaybi et al, 2010;Schittenhelm et al, 2010;Bisceglia et al, 2010Bisceglia et al, , 2011aKang et al, 2010;Inagaki et al, 2011;Salvatorelli et al, 2011Salvatorelli et al, , 2015Wang et al, 2011;Singh et al, 2012;Magro et al, 2014aMagro et al, ,b, 2015a. Among these tumors, cytoplasmic expression of WT1 was also reported in a few series of rhabdomyosarcomas (Carpentieri et al, 2002;Sebire et al, 2005;Bisceglia et al, 2010) or in single case reports (Fraternali-Orcioni et al, 2010;Bisceglia et al, 2011a,b).…”